Imricor Medical Systems (ASX:IMR) said all technical goals of the sensing and image-guided neurological therapies, cardiac electrophysiology, and tumor Treatments consortium related to its NorthStar 3D mapping system operating on Philips Medical Systems' MRI platform were achieved during testing, according to a Thursday filing with the Australian Securities Exchange.
The testing was conducted over 14 hours at Amsterdam University Medical Center on Oct. 10, the filing said.
Philips and the company are now working on full commercialization efforts for NorthStar on the Philips platform, according to the filing.
Imricor Medical Systems' shares rose 8% in morning trade Friday and earlier hit their highest since January 2022.
Price (AUD): $0.80, Change: $+0.060, Percent Change: +8.11%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。